Humanwell Healthcare (600079.SH): R-ketamine hydrochloride injection approved to conduct clinical trials.

16:11 13/05/2026

ST Renfu (600079.SH) announcement, the company's holding subsidiary Yichang Renfu Pharmaceutical Co., Ltd. ("Yichang Renfu", the company holds 80% of its equity) recently received the approval issued by the National Medical Products Administration for the clinical trial approval notice for Ketamine Hydrochloride Injection, allowing clinical trials for depression with acute suicidal thoughts or behavior.

Humanwell Healthcare (600079.SH) announced that its holding subsidiary Yichang Renfu Pharmaceutical Co., Ltd. ("Yichang Renfu", of which the company owns 80% of the shares) recently received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for the approval of Ketamine Hydrochloride Injection for clinical trials in patients with acute suicidal thoughts or behaviors associated with depression.

SINOMEDIA (00623) spent HKD 310,600 to repurchase 152,000 shares on May 13th.

HENLIUS (02696): The phase I clinical trial of HLX48 (an antibody drug conjugate targeting EGFR and c-MET for the treatment of advanced/metastatic solid tumors) for injection has been approved to be conducted in Australia.

KML TECH (08065) terminates stock incentive plan.

SINOMEDIA (00623) spent HKD 310,600 to repurchase 152,000 shares on May 13th.

KML TECH (08065) terminates stock incentive plan.